Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors

Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors

Abstract Background Although epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) have been the standard treatment for advanced EGFR‐mutant adenocarcinoma, the effects of upfront EGFR‐TKI use in unresectable stage III EGFR‐mutant adenocarcinoma remain unexplored. Here, we conducte...

Full description

Bibliographic Details
Main Authors: Sheng‐Yuan Wang, Ching‐Han Lai, Chian‐Wei Chen, Szu‐Chun Yang, Chao‐Chun Chang, Chia‐Ying Lin, Yi‐Ting Yen, Yau‐Lin Tseng, Po‐Lan Su, Chien‐Chung Lin, Wu‐Chou Su
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Thoracic Cancer
Subjects:
adenocarcinoma
chemoradiotherapy
epidermal growth factor receptor
stage III
tyrosine kinase inhibitors
Online Access:https://doi.org/10.1111/1759-7714.14237

Internet

https://doi.org/10.1111/1759-7714.14237

Similar Items